Soluble CD44 Molecules in Serum of Patients with Prostate Cancer and Benign Prostatic Hyperplasia

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 627-630

  Jung, K ^a   Lein, M ^a   Weiss, S ^a   Schnorr, D ^a   Henke, W ^a   Loening, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

BPH; Carcinoma immunology; Cell adhesion molecules; Prostate cancer; Tumour marker

Indexed keywords

CD44V5 ANTIGEN; CD44V6 ANTIGEN; CELL ADHESION MOLECULE; HERMES ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0029889593     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00634-6     Document Type: Article

References (21)

1. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interaction with extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 1993, 9, 541-573.
2. Albelda SM. Biology of disease. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993, 68, 4-17.
3. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal surface receptor for hyaluronate. Cell 1990, 61, 1303-1313.
4. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993, 268, 12,235-12,238.
5. Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993, 21, 1225-1229.
6. Stamenkovic I, Aruffo A, Aminot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate bearing cells. EMBO J 1991, 10, 343-348.
7. Ponta H, Sleeman J, Herrlich P. Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochim Biophys Acta 1994, 1198, 1-10.
8. Heider KH, Hofmann M, Hors E, et al. A human homologue of the rat metastatic-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993, 120, 227-233.
9. Koopman G, Heider KH, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993, 177, 897-904.
10. Dall P, Heider KH, Hekele A, et al. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994, 54, 3337-3341.
11. Wielenga VJM, Heider KH, Johan G, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression Cancer Res 1991, 51, 5292-5297.
12. Hofmann M, Rudy W, Zöller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991, 51, 5292-5297.
13. Guo Y, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994, 54, 422-426.
14. Solberg HE. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987, 25, 645-656.
15. Steger G, Mader R, Djavanmard M, Gnant M, Jakesz R. sCD44v5 bei colorektalem Karzinom. CD44-Symposium, 9 June 1994, Vienna.
16. Kitt EM, Ruckser R, Huber K, et al. sCD44 Standard und die Varianten (v5) and (v6) bei Mammakarzinom. Lab Med 1995, 19, 103.
17. Dall P, Heider KH, Sinn HP. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995, 60, 471-477.
18. Kainz C, Tempfer C, Winkler S, Sliutz G, Koelbl H, Reinthaller A. Serum CD44 splice variants in cervical cancer patients. Cancer Lett 1995, 90, 231-234.
19. Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumors. Cancer Res 1994, 54, 1381-1387.
20. Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett 194, 76, 63-69.
21. Matsumara Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992, 340, 1053-1058.